Semaglutide Capsules (7mg)
-
Regular Price
-
$199.95
-
Sale Price
-
$199.95
-
Regular Price
-
Sold Out
-
Unit Price
- per
- Regular Price
- $199.95
- Sale Price
- $199.95
- Regular Price
- Unit Price
- per
Semaglutide Capsules
Say goodbye to injections and hello to convenience with the first-ever Semaglutide capsules, available exclusively from NordSci. Containing the same active ingredient as Ozempic® and Wegovy®, these capsules deliver effective results at a fraction of the price.
Specification:
| Unit Size |
7 mg/capsule |
| Unit Quantity | 30 capsules |
| Purity (HPLC) |
99.8% |
| Sequence | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(PEG2-PEG2-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| Molecular Formula |
C187H291N45O59 |
| Molecular Weight |
4111.12 |
| CAS |
910463-68-2 |
| Appearance | White capsule |
| Source | Chemical Synthesis |
| Storage |
Store the capsules in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
Semaglutide, commonly known as Ozempic, is a derivative of GLP-1, a naturally occurring peptide hormone that regulates blood sugar levels and insulin secretion. Research indicates that Semaglutide can potentially improve heart, liver, and lung function while also slowing or preventing the effects of Alzheimer's disease. By delaying gastric emptying and reducing intestinal motility, Semaglutide effectively decreases appetite. This GLP-1 analog stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner.
GLP-1, a short peptide hormone approximately 30-31 amino acids in length, plays a crucial role in lowering blood sugar levels by enhancing insulin secretion. It has also been associated with neurotrophic effects in the brain and is involved in protecting beta cell insulin stores and promoting nervous system function. In the gastrointestinal system, GLP-1 significantly reduces appetite by delaying gastric emptying and decreasing intestinal motility. Moreover, preliminary studies have revealed the potential impacts of GLP-1 on various organs such as the heart, fat, muscles, bones, liver, lungs, and kidneys.
While GLP-1 research primarily focuses on treating and preventing diabetes, as well as suppressing appetite, secondary research investigates its potential cardiovascular benefits. Recent studies also highlight the ability of GLP-1 to mitigate neurodegenerative diseases, particularly Alzheimer's, by slowing down or preventing the accumulation of amyloid beta plaques.
In a phase 3 clinical trial involving overweight or obese adults without diabetes, the efficacy of Semaglutide was assessed compared to a placebo, along with lifestyle modifications. A total of 1961 participants received weekly subcutaneous injections of 2.4 mg of Semaglutide or placebo over 68 weeks, while both groups received counseling on diet and exercise. The primary outcomes measured were the percentage change in body weight and weight reduction of at least 5%.
At week 68, the mean weight reduction was significantly higher in the Semaglutide group compared to the placebo group (14.9% vs. 2.4%; estimated difference of -12.4 percentage points; 95% CI, -13.4 to -11.5). Furthermore, a greater proportion of participants in the Semaglutide group achieved a weight loss of at least 5% compared to the placebo group (86.4% vs. 31.5%). Regarding safety, mild to moderate adverse events, mainly gastrointestinal, were reported, leading to treatment discontinuation in 7.0% of the Semaglutide group and 3.1% of the placebo group. Serious adverse events, primarily gastrointestinal and hepatobiliary, occurred more frequently in the Semaglutide group.
It was concluded overweight or obese adults without diabetes experienced clinically relevant weight loss when treated with weekly injections of Semaglutide (2.4 mg) in conjunction with lifestyle modifications.
The primary concern for peptide researchers today is product purity. Saveco Meds guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION.
ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
Administer one capsule per day in the morning at least 30 minutes before the first food, drink, or other oral medicines of the day with a sip of plain water only (no more than 4 ounces).
Capsule should be swallowed whole. Capsule should not be split, crushed, or chewed. Do not administer more than directed.
If a dose is missed, skip the missed dose and go back to regular dosing schedule. Do not double dose.
Store the capsules in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Semaglutide Capsules (7 mg) – Product Description
Semaglutide Capsules (7 mg) are a high-purity, oral GLP-1 receptor agonist formulation manufactured for controlled laboratory research. These capsules are designed for preclinical investigations into incretin biology, metabolic signaling, and oral peptide delivery, providing researchers with a standardized, convenience-focused format for experimental models.
Semaglutide Capsules Research Specifications:
| Unit Size | 7 mg/capsule (Semaglutide content) |
| Unit Quantity | As indicated on product label |
| Form | Hard gelatin capsules with semaglutide in a research-grade oral formulation |
| Purity (HPLC) | > 99% (peptide content) |
| Peptide Class | Long-acting GLP-1 receptor agonist |
| Molecular Formula (Semaglutide) | C187H291N45O59 |
| Molecular Weight (Semaglutide) | ≈ 4,113 g/mol |
| CAS Number | 910463-68-2 |
| Appearance | Encapsulated white/off-white lyophilized peptide blend |
| Source | Chemical synthesis |
| Storage Conditions | Store Semaglutide Capsules in a cool, dry environment at 2–8 °C, protected from light and moisture. Do not freeze. Follow on-label stability guidance for optimal research performance. |
| Research Use Only | This product is intended strictly for laboratory research use. Not for human consumption, clinical application, or therapeutic use. Please review our terms of service prior to ordering. |
What Are Semaglutide Capsules? Research Background and Mechanism
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist engineered for enhanced stability and extended half-life relative to native GLP-1. In preclinical and clinical research, semaglutide has been widely used as a model compound to study incretin signaling, appetite regulation pathways, and glucose homeostasis mechanisms.1,2
Oral semaglutide formulations combine the peptide with specialized excipients to support gastrointestinal transit and peptide uptake in research settings. This allows investigators to compare oral peptide delivery with parenteral administration, assess pharmacokinetic and pharmacodynamic profiles, and model exposure–response relationships under different dosing conditions.2
At the receptor level, semaglutide selectively activates GLP-1 receptors expressed in pancreatic, central nervous system, and peripheral tissues, enabling detailed interrogation of:
- Insulin and glucagon secretion dynamics
- Gastric emptying and gut–brain axis signaling
- Energy intake, satiety, and appetite-related pathways
- Cardiometabolic biomarkers and vascular endpoints in preclinical models
Semaglutide Capsules (7 mg) extend this body of work by providing a standardized oral research format that can be integrated into diet-induced obesity models, combination-peptide studies, or comparative GLP-1 investigations alongside other incretin or multi-agonist compounds.
Important Research Notice: Nordsci semaglutide products are manufactured under strict quality-control specifications and verified via independent third-party analytical testing. Each lot is accompanied by Certificate of Analysis (COA) documentation detailing peptide identity and purity for laboratory use.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
Semaglutide Capsules in Preclinical Research
Metabolic and Glycemic Models: In animal studies and translational models, semaglutide has been used extensively to investigate GLP-1–mediated effects on fasting glucose, post-prandial glycemic excursions, and β-cell–centric outcomes.1,3 Capsule formulations provide an oral route to model real-world exposure patterns, adherence considerations, and dosing-schedule scenarios in controlled research environments.
Body-Weight and Appetite Research: GLP-1 signaling plays a central role in appetite regulation, satiety, and energy intake. Oral semaglutide has been characterized in preclinical and clinical research for its impact on body weight trajectories, caloric intake, and eating-behavior endpoints over time, creating a robust data set for weight-management and energy-balance investigations.1,3
Route-of-Administration Comparisons: Semaglutide Capsules (7 mg) are well suited for experimental designs that compare oral GLP-1 delivery to subcutaneous semaglutide or other parenteral peptides. Such studies can quantify differences in pharmacokinetics, variability in exposure, and downstream biomarker dynamics between oral and injectable modalities.
Exploratory Combination Studies: Because GLP-1 agonism is frequently evaluated alongside other metabolic or neuroendocrine pathways, semaglutide capsules can be integrated into stacked or combination research models—for example, pairing with energy-support, recovery, or stress-response peptides in multi-arm designs—to study synergistic or additive effects in vivo.
Reconstitution and Handling for Laboratory Use
Semaglutide Capsules (7 mg) arrive as ready-to-use oral units and do not require reconstitution in the same way as lyophilized vials. However, certain research workflows may call for capsule opening and dispersion of contents for in vitro or ex vivo applications.
General Handling Guidance:
- Store capsules at 2–8 °C in original, sealed packaging until use.
- Protect from moisture, heat, and direct light.
- If capsule contents are to be used in solution, handle under appropriate aseptic conditions and prepare in a suitable buffer (for example, pH-controlled aqueous solutions) consistent with institutional protocols.
- Dispose of unused material and consumables according to your institution’s peptide and pharmaceutical waste policies.
Note: Handling and solution preparation steps will vary based on the experimental design (in vitro vs. in vivo) and should always follow local biosafety, animal-care, and chemical-handling standards.
Certificate of Analysis (COA) and Quality Assurance
Each Semaglutide Capsules (7 mg) lot is supported by third-party analytical testing, typically including high-performance liquid chromatography (HPLC) for purity assessment and mass spectrometry for peptide identity. COA documentation is supplied with each shipment and can also be requested from Nordsci Peptides for audit, compliance, or archival purposes.
Where to Buy Semaglutide Capsules for Research Purposes
Research teams evaluating oral GLP-1 agonists should prioritize suppliers that provide transparent documentation and consistent manufacturing practices. Nordsci Peptides focuses on high-purity peptide production for qualified laboratories, offering both injectable semaglutide and capsule-based formulations to support a broad range of study designs.
Procurement and Compliance Considerations:
- Confirm that products are labeled and sold strictly for research use only.
- Ensure that GLP-1 products are accompanied by COA and stability data suitable for institutional records.
- Align ordering and storage processes with internal SOPs, IACUC guidance (for animal work), and any applicable regulatory frameworks governing peptide research in your jurisdiction.
Compliance Reminder: Semaglutide Capsules (7 mg) are not approved for human use, medical treatment, or over-the-counter distribution. All applications must be confined to preclinical and in vitro research conducted by qualified professionals.
Scientific References
- Davies M, et al. “Oral semaglutide: A GLP-1 analogue in a tablet formulation.” Diabetes Obes Metab. 2017.
- Granhall C, et al. “Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Healthy Subjects and Subjects with Type 2 Diabetes.” Clin Pharmacokinet. 2019.
- Husain M, et al. “Oral Semaglutide and Cardiometabolic Outcomes in Type 2 Diabetes.” N Engl J Med. 2019.
- Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” N Engl J Med. 2016.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: “in glass”) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.